Prevalence and Temporal Trends of Multidrug-resistant Tuberculosis in Iran from 1981 to 2023: A Systematic Review and Meta-analysis.

IF 1.6 Q4 INFECTIOUS DISEASES International Journal of Mycobacteriology Pub Date : 2024-07-01 Epub Date: 2024-09-14 DOI:10.4103/ijmy.ijmy_162_24
Saman Ayoubi, Parissa Farnia, Poopak Farnia, Jalaledin Ghanavi, Ali Akbar Velayati
{"title":"Prevalence and Temporal Trends of Multidrug-resistant Tuberculosis in Iran from 1981 to 2023: A Systematic Review and Meta-analysis.","authors":"Saman Ayoubi, Parissa Farnia, Poopak Farnia, Jalaledin Ghanavi, Ali Akbar Velayati","doi":"10.4103/ijmy.ijmy_162_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multidrug-resistant tuberculosis (MDR-TB) is a serious threat to global tuberculosis (TB) control efforts. This study aims to investigate the trend of MDR-TB prevalence in Iran over 20 years.</p><p><strong>Methods: </strong>A systematic literature search was conducted in various databases, including PubMed, Embase, and Web of Science, from 1981 to 2023. Studies reporting the prevalence of MDR-TB in Iran were included in the meta-analysis. Statistical analysis was performed using Comprehensive Meta-Analysis software.</p><p><strong>Results: </strong>A total of 58 studies from different provinces of Iran were included in the meta-analysis. The majority of studies were from Tehran (n = 33), Kermanshah (n = 5), Mashhad (n = 4), and Tabriz (n = 4) provinces. Overall, 1885 cases of MDR-TB were reported in Iran during the study period. The highest number of MDR-TB cases was reported in 2000 (582 cases) and the lowest in 2001 (1 case). An increasing trend in MDR-TB prevalence was observed, particularly between 2018 and 2019. The pooled prevalence of MDR-TB in Iran was 12.31% (95% CI: 11.83-12.80) using the fixed-effects model and 20.21% (95% CI: 15.70-26.01) using the random-effects model. No evidence of publication bias was found.</p><p><strong>Conclusion: </strong>The results of this comprehensive meta-analysis highlight the increasing trend of MDR-TB in Iran over the past two decades. This underscores the urgent need for strengthening TB control strategies, including improved surveillance, case detection, treatment, and management of MDR-TB in the country. Developing diagnostic and treatment approaches for MDR-TB should be prioritized by Iranian medical universities and public health authorities.</p>","PeriodicalId":14133,"journal":{"name":"International Journal of Mycobacteriology","volume":"13 3","pages":"320-330"},"PeriodicalIF":1.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Mycobacteriology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ijmy.ijmy_162_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multidrug-resistant tuberculosis (MDR-TB) is a serious threat to global tuberculosis (TB) control efforts. This study aims to investigate the trend of MDR-TB prevalence in Iran over 20 years.

Methods: A systematic literature search was conducted in various databases, including PubMed, Embase, and Web of Science, from 1981 to 2023. Studies reporting the prevalence of MDR-TB in Iran were included in the meta-analysis. Statistical analysis was performed using Comprehensive Meta-Analysis software.

Results: A total of 58 studies from different provinces of Iran were included in the meta-analysis. The majority of studies were from Tehran (n = 33), Kermanshah (n = 5), Mashhad (n = 4), and Tabriz (n = 4) provinces. Overall, 1885 cases of MDR-TB were reported in Iran during the study period. The highest number of MDR-TB cases was reported in 2000 (582 cases) and the lowest in 2001 (1 case). An increasing trend in MDR-TB prevalence was observed, particularly between 2018 and 2019. The pooled prevalence of MDR-TB in Iran was 12.31% (95% CI: 11.83-12.80) using the fixed-effects model and 20.21% (95% CI: 15.70-26.01) using the random-effects model. No evidence of publication bias was found.

Conclusion: The results of this comprehensive meta-analysis highlight the increasing trend of MDR-TB in Iran over the past two decades. This underscores the urgent need for strengthening TB control strategies, including improved surveillance, case detection, treatment, and management of MDR-TB in the country. Developing diagnostic and treatment approaches for MDR-TB should be prioritized by Iranian medical universities and public health authorities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1981-2023年伊朗耐多药结核病的流行率和时间趋势:系统回顾与元分析》。
背景:耐多药结核病(MDR-TB)对全球结核病(TB)控制工作构成严重威胁。本研究旨在调查伊朗 20 年来 MDR-TB 的流行趋势:在各种数据库(包括 PubMed、Embase 和 Web of Science)中对 1981 年至 2023 年的文献进行了系统检索。报告伊朗 MDR-TB 患病率的研究被纳入荟萃分析。统计分析使用 Comprehensive Meta-Analysis 软件进行:荟萃分析共纳入了来自伊朗不同省份的 58 项研究。大多数研究来自德黑兰省(33 项)、克尔曼沙阿省(5 项)、马什哈德省(4 项)和大不里士省(4 项)。在研究期间,伊朗共报告了 1885 例耐药结核病例。2000 年报告的耐药结核病例数量最多(582 例),2001 年最少(1 例)。观察到 MDR-TB 患病率呈上升趋势,尤其是在 2018 年至 2019 年期间。采用固定效应模型,伊朗MDR-TB的汇总流行率为12.31%(95% CI:11.83-12.80);采用随机效应模型,伊朗MDR-TB的汇总流行率为20.21%(95% CI:15.70-26.01)。没有发现发表偏倚的证据:这项综合荟萃分析的结果突出表明,在过去二十年里,伊朗的耐药结核病呈上升趋势。这突出表明,伊朗急需加强结核病控制策略,包括改进 MDR-TB 的监测、病例检测、治疗和管理。伊朗医科大学和公共卫生当局应优先考虑开发 MDR-TB 的诊断和治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.20
自引率
25.00%
发文量
62
审稿时长
7 weeks
期刊最新文献
Methods for the Inactivation of Mycobacterium tuberculosis: a Systematic Review of the Literature. Molecular Identification of Mycobacterium leprae in the Leprosy Patients. Optimal Positive End-expiratory Pressure Levels in Tuberculosis-associated Acute Respiratory Distress Syndrome. Prevalence and Temporal Trends of Multidrug-resistant Tuberculosis in Iran from 1981 to 2023: A Systematic Review and Meta-analysis. Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1